SCHEMBL17429059

SCHEMBL17429059

C[C@H]1C[C@H](Nc2ncncc2C(=O)c2cc(C(C#CC3CC3)O[Si](C)(C)C(C)(C)C)c(Cl)s2)C[C@@H]1CO

nearest known ligand 0.45

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
SAE1 Q9UBE0 20/20 0.45
UBA2 Q9UBT2 20/20 0.45
NAE1 Q13564 14/20 0.45
UBA3 Q8TBC4 14/20 0.45
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17429061 0.95 SAE1 (0.44) SAE1UBA2NAE1UBA3CA1
SCHEMBL17421707 0.90 SAE1 (0.43) SAE1UBA2NAE1UBA3CA1
SCHEMBL22426164 0.90 SAE1 (0.43) SAE1UBA2NAE1UBA3CA1
SCHEMBL17421728 0.90 SAE1 (0.43) SAE1UBA2NAE1UBA3CA1
SCHEMBL17429054 0.88 SAE1 (0.49) SAE1UBA2NAE1UBA3CA1
SCHEMBL17421670 0.85 SAE1 (0.42) SAE1UBA2NAE1UBA3CA1
SCHEMBL21800788 0.85 SAE1 (0.42) SAE1UBA2NAE1UBA3CA1
SCHEMBL17421688 0.85 SAE1 (0.42) SAE1UBA2NAE1UBA3CA1
SCHEMBL17429055 0.82 SAE1 (0.47) SAE1UBA2NAE1UBA3CA1
SCHEMBL17429058 0.81 SAE1 (0.48) SAE1UBA2NAE1UBA3CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293522-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-09-21 US disclosed
US-20170216290-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-08-03 US disclosed
US-9683003-B2 Heteroaryl compounds useful as inhibitors of SUMO activating enzyme MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-06-20 US disclosed
US-20170002032-A9 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME MILLENNIUM PHARMACEUTICALS, INC. (US) 2017-01-05 US disclosed
US-20160009744-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170002032-A9 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME SAE1, SUMO1, SUMO3 SAE1 1/4885UBA2 5/4885NAE1 88/4885
US-20230293522-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME SAE1, SUMO1, SUMO3 SAE1 1/4885UBA2 5/4885NAE1 88/4885
US-20170216290-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME SAE1, SUMO1, SUMO3 SAE1 1/4885UBA2 5/4885NAE1 88/4885
US-20160009744-A1 HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME SAE1, SUMO1, SUMO3 SAE1 1/4885UBA2 5/4885NAE1 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.